If you go by Sinclair's market valuation of the drug given how many people suffer from the condition then it's a billion dollar company so $15 to $20 per share given there is no further dilution. I am not sure how accurate her valuation is as it's a fairly obscure condition so I have it conservatively valued at $8-10 a share if phase 3 results are positive. I also think a buyer will be lined up shortly after results so potentially no other CR will be required (if FDA align with EMA and grant one study)
If you go by Sinclair's market valuation of the drug given...
-
- There are more pages in this discussion • 34 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
